BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11512313)

  • 1. One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre.
    McGeown MG; Douglas JF; Middleton D
    Clin Transpl; 2000; ():193-202. PubMed ID: 11512313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data.
    Joss N; Rodger RS; McMillan MA; Junor BJ
    Transplantation; 2007 Mar; 83(5):582-7. PubMed ID: 17353778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients.
    Herman M; Weinstein T; Korzets A; Chagnac A; Ori Y; Zevin D; Malachi T; Gafter U
    J Lab Clin Med; 2001 Jan; 137(1):14-20. PubMed ID: 11150019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
    Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
    Shabtai M; Ben-Haim M; Zemer D; Malinger-Saavedra P; Rosin D; Kuriansky J; Lustig S; Shabtai EL; Shapira Z; Ayalon A
    Isr Med Assoc J; 2002 Nov; 4(11 Suppl):935-9. PubMed ID: 12455184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors.
    Wisgerhof HC; Edelbroek JR; de Fijter JW; Haasnoot GW; Claas FH; Willemze R; Bavinck JN
    Transplantation; 2010 May; 89(10):1231-8. PubMed ID: 20410852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open randomized study comparing immunosuppression therapy initiated before or after kidney transplantation in haploidentical living recipients.
    Câmara NO; Dias MF; Pacheco-Silva A
    Clin Transplant; 2004 Aug; 18(4):450-5. PubMed ID: 15233825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
    Carstens J
    Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
    Grimbert P; Baron C; Fruchaud G; Hemery F; Desvaux D; Buisson C; Chopin D; Dahmane D; Remy P; Pastural M; Abbou C; Weil B; Lang P
    Transpl Int; 2002 Nov; 15(11):550-5. PubMed ID: 12461659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens.
    Dantal J; Hourmant M; Cantarovich D; Giral M; Blancho G; Dreno B; Soulillou JP
    Lancet; 1998 Feb; 351(9103):623-8. PubMed ID: 9500317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
    Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of azathioprine versus cyclosporine-based therapy in primary haplo-identical live-donor kidney transplantation: a 20-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
    Saudi J Kidney Dis Transpl; 2008 Jul; 19(4):564-70. PubMed ID: 18580014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J; Citterio F; Nanni G; Favi E; Tondolo V; Spagnoletti G; Salerno MP; Castagneto M
    Transplant Proc; 2006 May; 38(4):1034-6. PubMed ID: 16757255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients.
    Fortina AB; Piaserico S; Caforio AL; Abeni D; Alaibac M; Angelini A; Iliceto S; Peserico A
    Arch Dermatol; 2004 Sep; 140(9):1079-85. PubMed ID: 15381547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low incidence of neoplasia in heart and heart-lung transplant recipients receiving triple-drug immunosuppression.
    Olivari MT; Diekmann RA; Kubo SH; Braunlin E; Jamieson SW; Ring WS
    J Heart Transplant; 1990; 9(6):618-21. PubMed ID: 2277297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
    Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.